{"organizations": [], "uuid": "20c1f87c80b773002a9ef54fbbde902da974e141", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/22/globe-newswire-htg-molecular-diagnostics-reports-fourth-quarter-and-full-year-2017-results.html", "country": "US", "domain_rank": 767, "title": "HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T23:01:00.000+02:00", "replies_count": 0, "uuid": "20c1f87c80b773002a9ef54fbbde902da974e141"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/22/globe-newswire-htg-molecular-diagnostics-reports-fourth-quarter-and-full-year-2017-results.html", "ord_in_thread": 0, "title": "HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "tucson", "sentiment": "none"}, {"name": "ariz.", "sentiment": "none"}], "organizations": [{"name": "htg molecular diagnostics", "sentiment": "negative"}, {"name": "htg molecular diagnostics , inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Revenue increased 442% and 188%, respectively, compared to the three and twelve month periods in the prior year driven by development efforts supporting Pharma clinical programs\nTUCSON, Ariz., March 22, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported its financial results for the fourth quarter and year ended December 31, 2017.\nRecent Accomplishments & Highlights:\nAchieved revenue of $7.9 million and $14.8 million for the three and twelve months ended December 31, 2017, respectively, which represents a 442% and 188% increase over the respective periods in 2016. Fourth quarter and full year 2017 revenue was driven primarily by the company’s collaborative development services programs.\nCompleted underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, in January 2018. The aggregate net proceeds from the offering were approximately $37.7 million, after deducting the underwriting discounts and commissions and offering expenses.\nEntered into a third statement of work for a new clinical assay development program under the company’s Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited, (QML), a wholly owned subsidiary of QIAGEN, N.V. (NYSE:QGEN), in connection with a sponsor project agreement between QML and a pharmaceutical company, in January 2018.\nEntered into a new master collaboration agreement for translational programs with Merck KGaA, Darmstadt, Germany, in December 2017. The master collaboration agreement complements the previously announced master companion diagnostic agreement with Merck KGaA, and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA, in the United States and Canada.\n“We entered 2017 with specific goals to accelerate customer adoption, expand our BioPharma pipeline, initiate commercialization of our CE/IVD products in Europe and strengthen our balance sheet. 2017 exceeded our performance expectations, and we move into 2018 looking forward to continuing our momentum,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics.\nFourth Quarter 2017 Financial Results:\nRevenue for the fourth quarter of 2017 was $7.9 million, compared to $1.5 million for the fourth quarter of 2016. Net loss from operations for the fourth quarter of 2017 was $1.7 million, compared to $5.2 million for the fourth quarter of 2016.\nNet loss for the fourth quarter of 2017 was $1.9 million, compared to $5.7 million for the fourth quarter of 2016. Net loss per share was $(0.15) for the fourth quarter of 2017 compared to $(0.76) for the fourth quarter of 2016.\nFull Year 2017 Financial Results:\nRevenue for the year ended December 31, 2017 was $14.8 million, compared to $5.1 million for the year ended December 31, 2016. Net loss from operations for the year ended December 31, 2017 was $17.7 million, compared to $24.3 million for year ended December 31, 2016.\nNet loss for the year ended December 31, 2017 was $19.0 million, compared to $26.0 million for the year ended December 31, 2016. Net loss per share for the year ended December 31, 2017 was $(1.79) compared to $(3.66) for the year ended December 31, 2016.\nHTG ended 2017 with $10.0 million in cash and equivalents and current liabilities of approximately $13.3 million plus an additional $11.0 million in non-current liabilities. Net proceeds from the underwritten public offering completed on January 23, 2018 were approximately $37.7 million, after deducting for underwriting discounts and commissions and offering expenses.\nConference Call and Webcast:\nHTG will host an investment community conference call today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details follow:\nDate: Thursday, March 22 Time: 4:30pm Eastern Time Toll Free: (800) 239-9838 International: (323) 794-2551 Conference ID: 7843064 Webcast: http://public.viavid.com/index.php?id=128362 About HTG:\nHTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.\n-Financial tables follow-\nHTG Molecular Diagnostics, Inc. Statements of Operations Three Months Ended December 31, Years Ended December 31, 2017 2016 2017 2016 Revenue: Product and product-related services $ 2,374,951 $ 1,457,781 $ 6,797,255 $ 5,132,730 Collaborative development services 5,529,207 — 7,962,312 — Total revenue 7,904,158 1,457,781 14,759,567 5,132,730 Cost of revenue 1,350,613 1,234,429 4,971,806 4,135,884 Gross margin 6,553,545 223,352 9,787,761 996,846 Operating expenses: Selling, general and administrative 4,603,491 4,083,832 17,513,742 17,427,777 Research and development 3,632,256 1,384,503 9,996,627 7,900,311 Total operating expenses 8,235,747 5,468,335 27,510,369 25,328,088 Operating loss (1,682,202 ) (5,244,983 ) (17,722,608 ) (24,331,242 ) Other expense, net (237,895 ) (422,239 ) (1,234,488 ) (1,698,190 ) Net loss before income taxes (1,920,097 ) (5,667,222 ) (18,957,096 ) (26,029,432 ) Provision for income taxes 1,898 5,859 2,921 10,118 Net loss $ (1,921,995 ) $ (5,673,081 ) $ (18,960,017 ) $ (26,039,550 ) Net loss per share, basic and diluted $ (0.15 ) $ (0.76 ) $ (1.79 ) $ (3.66 ) Shares used in computing net loss per share, basic and diluted 12,979,143 7,488,842 10,597,318 7,113,075\nHTG Molecular Diagnostics, Inc. Balance Sheets December 31, 2017 2016 Assets Current assets: Cash and cash equivalents $ 9,968,600 $ 7,507,659 Short-term investments available-for-sale, at fair value — 4,304,901 Accounts receivable 6,356,268 1,377,441 Inventory, net 1,180,521 1,511,053 Prepaid expenses and other 443,068 433,328 Total current assets 17,948,457 15,134,382 Deferred offering costs 2,953 49,630 Property and equipment, net 3,304,890 3,270,197 Total assets $ 21,256,300 $ 18,454,209 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 2,438,798 $ 761,663 Accrued liabilities 3,746,786 1,670,286 Deferred revenue - current 665,882 335,659 NuvoGen obligation - current 496,442 604,751 Term loan payable - current, net of discount and debt issuance costs of $64,807 at December 31, 2017 and $0 at December 31, 2016 5,793,599 6,389,782 Other current liabilities 200,460 258,850 Total current liabilities 13,341,967 10,020,991 Term loan payable - non-current, net of discount and debt issuance costs of $0 at December 31, 2017 and $263,378 at December 31, 2016 — 5,389,137 NuvoGen obligation - non-current, net of discount 7,520,913 8,017,356 Convertible note, related party - net of debt issuance costs 2,960,760 Other non-current liabilities 492,197 619,587 Total liabilities 24,315,837 24,047,071 Commitments and Contingencies Total stockholders’ deficit (3,059,537 ) (5,592,862 ) Total liabilities and stockholders' deficit $ 21,256,300 $ 18,454,209 Contact:\nAshley Robinson\nLifeSci Advisors, LLC\nPhone: (617) 775-5956\nEmail: arr@lifesciadvisors.com\nTJ Johnson\nPresident / CEO\nHTG Molecular Diagnostics\nPhone: (520) 547-2827 x130\nEmail: tjjohnson@htgmolecular.com\nSource:HTG Molecular Diagnostics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=0f_IaJgsZNDjuRjuhL6Fea9vFkUgE-xTVAbQDU8F0UmR6cyKij1SaF_cityqU9k8AO72GQQm4eYh-s0jovEghYbAHtGpSsQx3099qRhAX8Hoi77vRshHnScvY3w0Wn9a", "https://www.globenewswire.com/Tracker?data=7h2wAiFMPCDczbZnFLrzSamOiPs73W1lWxgEz3nfi8Dq0zF5R4Sda3rse3ff_28KLMxKbskFmvLU2Iu4aRCRGtXmo2Yp25RYJ77UxamswwY=", "https://www.globenewswire.com/Tracker?data=DbEd5Zy14lSDySmICROlqVABkOsJhnA06hQzVdvspQmGg4Im7uEuN34EHiqw053PTylQ65-CUT_GNGeGb18S1PgkZ1bJxwz9K7OY0UfAHKE=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/2ab311fb-aa9c-4505-adce-ed9ce3bb6490", "http://public.viavid.com/index.php?id=128362"], "published": "2018-03-22T23:01:00.000+02:00", "crawled": "2018-03-22T22:45:50.140+02:00", "highlightTitle": ""}